Zota Health Care Ltd
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.[1]
- Market Cap ₹ 1,547 Cr.
- Current Price ₹ 564
- High / Low ₹ 725 / 402
- Stock P/E
- Book Value ₹ 58.0
- Dividend Yield 0.18 %
- ROCE -7.32 %
- ROE -16.8 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Debtor days have improved from 76.6 to 55.1 days.
Cons
- Stock is trading at 9.73 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -2.03%
- Company has a low return on equity of -4.74% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 220 | |
| 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 220 | |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -0 |
| OPM % | 14% | 13% | 13% | 15% | 9% | 5% | 1% | 11% | 5% | 4% | -0% |
| 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 9 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 29 |
| Profit before tax | 3 | 3 | 5 | 6 | 8 | 4 | -0 | 12 | -5 | -16 | -37 |
| Tax % | 34% | 33% | 33% | 33% | 29% | 29% | -41% | 28% | 23% | -11% | |
| 2 | 2 | 3 | 4 | 6 | 3 | -0 | 9 | -6 | -14 | -35 | |
| EPS in Rs | 2.17 | 1.43 | 1.85 | 2.12 | 2.26 | 1.12 | -0.09 | 3.54 | -2.29 | -5.55 | -13.02 |
| Dividend Payout % | 0% | 50% | 38% | 34% | 32% | 90% | -1,170% | 42% | -44% | -18% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 16% |
| 3 Years: | 19% |
| TTM: | 41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -219% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 16% |
| 1 Year: | 41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -5% |
| Last Year: | -17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 10 | 12 | 14 | 18 | 25 | 25 | 25 | 25 | 26 | 27 |
| Reserves | 5 | 3 | 4 | 4 | 51 | 44 | 42 | 64 | 55 | 64 | 132 |
| 3 | 6 | 5 | 5 | 0 | 0 | 0 | 15 | 45 | 95 | 107 | |
| 5 | 10 | 14 | 17 | 21 | 20 | 19 | 35 | 33 | 43 | 51 | |
| Total Liabilities | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 317 |
| 8 | 10 | 9 | 8 | 10 | 15 | 14 | 29 | 62 | 103 | 137 | |
| CWIP | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 5 |
| Investments | 0 | 0 | 0 | 0 | 16 | 14 | 10 | 33 | 8 | 5 | 44 |
| 12 | 19 | 26 | 32 | 63 | 59 | 61 | 77 | 85 | 116 | 130 | |
| Total Assets | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 317 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 5 | -3 | 6 | -1 | 13 | -2 | -6 | |||
| -1 | -1 | 9 | -4 | 4 | -27 | 15 | -13 | |||
| -2 | -4 | -6 | -3 | -2 | 14 | -14 | 19 | |||
| Net Cash Flow | 0 | 0 | -1 | -1 | 1 | 1 | -1 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 71 | 79 | 77 | 95 | 112 | 99 | 102 | 73 | 55 |
| Inventory Days | 122 | 141 | 134 | 175 | 208 | 139 | 140 | 121 | 183 | 201 |
| Days Payable | 77 | 90 | 0 | 0 | 104 | 82 | 77 | 78 | 116 | 126 |
| Cash Conversion Cycle | 120 | 123 | 212 | 251 | 199 | 169 | 161 | 145 | 140 | 131 |
| Working Capital Days | 102 | 89 | 86 | 100 | 175 | 152 | 143 | 115 | 135 | 140 |
| ROCE % | 20% | 32% | 6% | -2% | 15% | -2% | -7% |
Documents
Announcements
-
Press Release (Revised)
15 November 2024 - Zota Health Care LImited has informed regarding a revised press release dated November 15, 2024, titled "Revised Press Release on Unaudited Financial Results for the …
-
Press Release
15 November 2024 - Zota Health Care LImited has informed regarding a press release dated November 15, 2024, titled "Press Release on Unaudited Financial Results for the quarter and …
-
Copy of Newspaper Publication
15 November 2024 - Zota Health Care LImited has informed about Copy of Newspaper Publication
-
Monitoring Agency Report
14 November 2024 - Monitoring agency report for monitoring the utilization of funds raised through Preferential Issue for the quarter ended on September 30, 2024
-
Statement of deviation(s) or variation(s) under Reg. 32
14 November 2024 - Zota Health Care LImited has informed about statement of deviation(s) or variation(s) under Reg. 32
Annual reports
Concalls
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Dec 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Dec 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
Business segments
Domestic sales (49% of FY21 revenue)[1] The is the oldest division and involves direct distribution of generic drugs, OTC products, and other pharmaceutical products through Company’s distribution network across India. Co. has 1050+ distributors across India and 3000+ products in its portfolio.